GHRS on Nasdaq
GH Research PLC
GH Research PLC is a pharmaceutical preparations company, listed on Nasdaq (GHRS).1
Price unavailable
Last updated Oct 21, 2026.
Overview
- TickerGHRS on Nasdaq1
- IndustryPharmaceutical Preparations1
- HeadquartersL21
- Incorporated inIreland3
- Business addressJoshua Dawson House, Dawson Street, Dublin 2, L2 D02 Ry953
- Filer categoryAccelerated filer, Emerging growth company3
See how the biggest companies compare on our leaderboards
Our principal expenditures since January 1, 2023 have been our research and development expenses, as more fully described elsewhere in this Annual Report.4 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
Financial statements
No quarterly figures reported.
Every line of the income statement as filed: the last 3 fiscal years, latest first.2
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Research and development | -$38.8M | -$35.0M | -$29.8M |
| General and administration | -$22.0M | -$15.3M | -$11.4M |
| Loss from operations | -$60.7M | -$50.3M | -$41.2M |
| Finance income | $11.1M | $9.9M | $9.0M |
| Finance expense | -$463.0K | -$717.0K | -$723.0K |
| Movement of expected credit loss | $42.0K | $66.0K | $1.0K |
| Foreign exchange gain/(loss) | $1.8M | $2.1M | -$2.6M |
| Total other income | $12.5M | $11.4M | $5.6M |
| Loss before tax | -$48.3M | -$39.0M | -$35.6M |
| Tax charge/(credit) | $0 | $0 | $0 |
| Loss for the year | -$48.3M | -$39.0M | -$35.6M |
| Fair value movement on marketable securities | -$127.0K | -$173.0K | -$95.0K |
| Currency translation adjustment | $785.0K | -$2.1M | $2.5M |
| Total comprehensive loss for the year | -$47.6M | -$41.2M | -$33.2M |
| Loss for the year | -$48.3M | -$39.0M | -$35.6M |
| Total comprehensive loss for the year | -$47.6M | -$41.2M | -$33.2M |
| Basic loss per share (in dollars per share) | -$0.79 | -$0.75 | -$0.68 |
| Diluted loss per share (in dollars per share) | -$0.79 | -$0.75 | -$0.68 |
No quarter-by-quarter statement was filed.
No quarterly figures reported.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.2
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $246.3M | $100.8M | $78.4M | $166.0M |
| Other financial assets | $0 | $19.4M | ||
| Marketable securities | $34.5M | $29.1M | ||
| Other current assets | $5.3M | $4.9M | ||
| Total current assets | $286.0M | $154.2M | ||
| Marketable securities | $0 | $33.3M | ||
| Property, plant and equipment | $620.0K | $748.0K | ||
| Other non-current assets | $1.6M | $0 | ||
| Total non-current assets | $2.3M | $34.0M | ||
| Total assets | $288.2M | $188.3M | ||
| Trade payables | $3.8M | $3.7M | ||
| Lease liability | $365.0K | $255.0K | ||
| Other current liabilities | $4.2M | $5.0M | ||
| Total current liabilities | $8.4M | $9.0M | ||
| Lease liability | $147.0K | $369.0K | ||
| Total non-current liabilities | $147.0K | $369.0K | ||
| Total liabilities | $8.5M | $9.3M | ||
| Share capital | $1.6M | $1.3M | ||
| Additional paid-in capital | $431.1M | $291.5M | ||
| Other reserves | $13.3M | $5.2M | ||
| Foreign currency translation reserve | -$11.8M | -$12.6M | ||
| Accumulated deficit | -$154.4M | -$106.4M | ||
| Total equity | $279.7M | $179.0M | $219.0M | $249.8M |
| Total liabilities and equity | $288.2M | $188.3M |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $246.3M | $100.8M | $78.4M | $166.0M |
| Other financial assets | $0 | $19.4M | ||
| Marketable securities | $34.5M | $29.1M | ||
| Other current assets | $5.3M | $4.9M | ||
| Total current assets | $286.0M | $154.2M | ||
| Marketable securities | $0 | $33.3M | ||
| Property, plant and equipment | $620.0K | $748.0K | ||
| Other non-current assets | $1.6M | $0 | ||
| Total non-current assets | $2.3M | $34.0M | ||
| Total assets | $288.2M | $188.3M | ||
| Trade payables | $3.8M | $3.7M | ||
| Lease liability | $365.0K | $255.0K | ||
| Other current liabilities | $4.2M | $5.0M | ||
| Total current liabilities | $8.4M | $9.0M | ||
| Lease liability | $147.0K | $369.0K | ||
| Total non-current liabilities | $147.0K | $369.0K | ||
| Total liabilities | $8.5M | $9.3M | ||
| Share capital | $1.6M | $1.3M | ||
| Additional paid-in capital | $431.1M | $291.5M | ||
| Other reserves | $13.3M | $5.2M | ||
| Foreign currency translation reserve | -$11.8M | -$12.6M | ||
| Accumulated deficit | -$154.4M | -$106.4M | ||
| Total equity | $279.7M | $179.0M | $219.0M | $249.8M |
| Total liabilities and equity | $288.2M | $188.3M |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.2
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Loss for the year | -$48.3M | -$39.0M | -$35.6M |
| Depreciation | $335.0K | $315.0K | $315.0K |
| Share-based compensation expense | $8.5M | $1.2M | $2.3M |
| Finance income | -$11.1M | -$9.9M | -$9.0M |
| Finance expense | $463.0K | $717.0K | $723.0K |
| Movement of expected credit loss | -$42.0K | -$66.0K | -$1.0K |
| Foreign exchange (gain)/loss | -$1.8M | -$2.1M | $2.6M |
| Movement in working capital | -$3.1M | $188.0K | $1.6M |
| Cash flows used in operating activities | -$55.0M | -$48.6M | -$37.0M |
| Finance expense paid | -$639.0K | -$723.0K | -$648.0K |
| Finance income received | $12.1M | $7.1M | $4.3M |
| Net cash used in operating activities | -$43.6M | -$42.3M | -$33.3M |
| Purchase of property, plant and equipment | -$121.0K | -$49.0K | -$100.0K |
| Purchase of other financial assets | $0 | $0 | -$54.0M |
| Proceeds from sale of other financial asset | $19.6M | $38.0M | $0 |
| Proceeds from redemptions and disposals of marketable securities | $26.7M | $27.2M | $0 |
| Cash flows from/(used in) investing activities | $46.2M | $65.1M | -$54.1M |
| Payment of lease liability | -$197.0K | -$304.0K | -$219.0K |
| Proceeds from equity public offering | $150.0M | $0 | $0 |
| Transaction costs from equity public offering | -$10.2M | $0 | $0 |
| Proceeds from share issuances | $0 | $0 | $15.0K |
| Net cash flows from/(used in) financing activities | $139.7M | -$304.0K | -$204.0K |
| Net increase/(decrease) in cash and cash equivalents | $142.3M | $22.5M | -$87.6M |
| Impact of foreign exchange on cash and cash equivalents | $3.2M | -$175.0K | $105.0K |
No quarter-by-quarter statement was filed.
Corporate structure
GH Research PLC sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of GH Research PLC
- Lynx1 Capital Management LP Filed SCHEDULE 13G/A on GH Research PLC, latest Aug 14, 2026 (9 filings since Feb 16, 2024)
- RA CAPITAL MANAGEMENT, L.P. Filed SCHEDULE 13G/A on GH Research PLC, latest Aug 14, 2026 (8 filings since Feb 14, 2022)
- Theis H. Terwey Filed SCHEDULE 13G/A on GH Research PLC, latest Nov 14, 2025 (4 filings since Feb 9, 2022)
- FMR LLC Filed SCHEDULE 13G/A on GH Research PLC, latest Aug 6, 2025 (7 filings since Feb 9, 2022)
- BIOTECHNOLOGY VALUE FUND L P Filed SCHEDULE 13G/A on GH Research PLC, latest May 15, 2025 (3 filings since Feb 14, 2022)
- RTW INVESTMENTS, LP Filed SCHEDULE 13G/A on GH Research PLC, latest May 15, 2025 (2 filings since Feb 14, 2024)
- Venrock Healthcare Capital Partners II, L.P. Filed SC 13G/A on GH Research PLC, latest Feb 14, 2024 (3 filings since May 27, 2022)
- Florian Schonharting Filed SC 13G/A on GH Research PLC, latest Feb 10, 2023 (2 filings since Feb 9, 2022)
- GH Research PLC L2
Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What GH Research PLC reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, net | $620.0K2 Dec 31, 2025 | $748.0K2 Dec 31, 2024 | −17.1% |
Investments
Leadership
Who has led GH Research PLC, and when. Pick a name to see everywhere that person has worked.
- Chief executive officerVelichka Valcheva Apr 2, 2026 to now9
- Chief operating officerAaron Luke Cameron Apr 2, 2026 to now10
Board members and other officers (5)
- Managing Director, IrelandMagnus Clemensen Halle Apr 2, 2026 to now11
- Board memberFlorian Schonharting Apr 1, 2026 to now12
- Board memberDermot John Hanley Apr 2, 2026 to now13
- Board memberMichael Forer Apr 2, 2026 to now14
- Board memberDuncan Moore Apr 17, 2026 to now15
Timeline
- Apr 2, 2026New chief executive Velichka Valcheva becomes CEO9
Calendar
Coming up
- Nov 5, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.23) a share, on Nov 6, 2025.16
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
183 filings to the SEC since October 2021: 7 annual reports, 12 insider forms, 38 large holders, 126 other. The latest 20:
- Oct 9, 20266-K EDGAR
- Sep 11, 20266-K EDGAR
- Sep 9, 20264 EDGAR
- Aug 14, 2026SCHEDULE 13G/A EDGAR
- Aug 14, 2026SCHEDULE 13G/A EDGAR
- Aug 13, 20264 EDGAR
- Aug 13, 20264 EDGAR
- Aug 13, 20264 EDGAR
- Aug 6, 20266-K EDGAR
- Jun 26, 20266-K EDGAR
- Jun 4, 20266-K EDGAR
- May 21, 20266-K EDGAR
- May 19, 2026EFFECT EDGAR
- May 18, 2026SCHEDULE 13G/A EDGAR
- May 15, 2026CORRESP EDGAR
- May 15, 2026SCHEDULE 13G/A EDGAR
- May 15, 2026UPLOAD EDGAR
- May 14, 20266-K EDGAR
- May 14, 2026F-3 EDGAR
- May 14, 2026424B5 EDGAR
The 183 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Lynx1 Capital Management LPSCHEDULE 13G/A, 9 filings Feb 16, 2024 to Aug 14, 202617
- RA CAPITAL MANAGEMENT, L.P.SCHEDULE 13G/A, 8 filings Feb 14, 2022 to Aug 14, 202618
- Theis H. TerweySCHEDULE 13G/A, 4 filings Feb 9, 2022 to Nov 14, 202519
- FMR LLCSCHEDULE 13G/A, 7 filings Feb 9, 2022 to Aug 6, 202520
- BIOTECHNOLOGY VALUE FUND L PSCHEDULE 13G/A, 3 filings Feb 14, 2022 to May 15, 202521
- RTW INVESTMENTS, LPSCHEDULE 13G/A, 2 filings Feb 14, 2024 to May 15, 202522
- Venrock Healthcare Capital Partners II, L.P.SC 13G/A, 3 filings May 27, 2022 to Feb 14, 202423
- Florian SchonhartingSC 13G/A, 2 filings Feb 9, 2022 to Feb 10, 202324
SEC filer profile
How GH Research PLC is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARGH Research PLC1
- CIK0001855129
- Filer statusAccelerated filer an emerging growth company; not a shell company4
- Incorporated inIreland4
- Fiscal year endsDecember 311
- Industry code (SIC)2834 Pharmaceutical Preparations1
- SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
- Business addressJoshua Dawson House, Dawson Street, Dublin 2, L2 D02 RY951
- Phone353 1 437 83341
- Shares outstanding62,029,395 shares as of Dec 31, 20254
- AuditorPricewaterhouseCoopers, Dublin, Ireland PCAOB ID 1366; no auditor attestation of internal control over financial reporting4
- On EDGAR sinceApr 20, 20211
- Filings199 in all: 6-K (105), SCHEDULE 13G/A (16), SC 13G/A (14), 3 (8), CORRESP (8), SC 13G (8), UPLOAD (7), 20-F (5)1
All 22 form types
4 (4), 424B5 (4), EFFECT (4), F-3 (3), S-8 (3), 20-F/A (2), 424B4 (1), 8-A12B (1), CERT (1), DRS (1), F-1 (1), F-1/A (1), F-1MEF (1), SCHEDULE 13G (1)
- Latest filingsAnnual report (20-F) Mar 5, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Ordinary shares, nominal value $0.025 per share | GHRS | Nasdaq |
From the cover page of the 20-F filed Mar 5, 2026 (Section 12(b) of the Exchange Act).4
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1SEC EDGARGH Research PLC filings on SEC EDGAR
- 2SEC EDGARGH Research PLC 10-K for fiscal 2025
- 3SEC EDGARGH Research PLC filings on SEC EDGAR
- 4
- 5SEC EDGARGH Research PLC 10-K for fiscal 2019
- 6SEC EDGARGH Research PLC 10-K for fiscal 2020
- 7SEC EDGARGH Research PLC 10-K for fiscal 2021
- 8SEC EDGARGH Research PLC 10-K for fiscal 2022
- 9
- 10
- 11
- 12SEC EDGARFlorian Schonharting, Board member
- 13SEC EDGARDermot John Hanley, Board member
- 14SEC EDGARMichael Forer, Board member
- 15SEC EDGARDuncan Moore, Board member
- 16NasdaqNasdaq calendar
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24